Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$1.55B in Q4 2024 → $1.65B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Arcus Biosciences Inc. | 58.8% | Unchanged | 31,424,760 | $969M |
| LB Lakefront Biotherapeutics | 30.3% | Unchanged | 16,707,477 | $500M |
| Assembly Biosciences Inc. | 8.3% | Added 10% | 4,977,089 | $137M |
| Kyverna Therapeutics Inc. | 2.2% | Unchanged | 4,126,119 | $36.8M |
| Xilio Therapeutics Inc. | 0.4% | Unchanged | 650,389 | $6.23M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2026 · filed August 03, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arcellx Inc | Exited | −6,720,803 | −$772M | — |
| Assembly Biosciences Inc. | Added | +471,698 | +$13M | 8.3% |
quarter ended March 31, 2026 · filed May 08, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Xilio Therapeutics Inc | Trimmed | −8,455,062 | −$71.1M | 0.3% |
quarter ended December 31, 2025 · filed February 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Merus N V | Exited | −452,527 | −$42.6M | — |
| Tango Therapeutics Inc | Exited | −4,854,443 | −$40.8M | — |
| LT Leap Therapeutics Inc | Exited | −5,319,148 | −$2.41M | — |
quarter ended September 30, 2025 · filed November 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Assembly Biosciences Inc | Added | +2,295,920 | +$58.8M | 6.4% |
| Hookipa Pharma Inc | Exited | −1,875,945 | −$2.35M | — |
| Allogene Therapeutics Inc | Exited | −1,156,689 | −$1.31M | — |
| Kalaris Therapeutics Inc | Exited | −317,789 | −$848K | — |
| IO Ikena Oncology Inc | Exited | −348,534 | −$467K | — |
| BB Barinthus Biotherapeutics Pl | Exited | −99,478 | −$92.5K | — |
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| IO Ikena Oncology Inc | Trimmed | −810,611 | −$1.09M | — |
| Kalaris Therapeutics Inc | Trimmed | −405,484 | −$1.08M | 0.1% |
| BB Barinthus Biotherapeutics Pl | Trimmed | −270,377 | −$251K | — |
quarter ended March 31, 2025 · filed May 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arcus Biosciences Inc | Added | +1,363,636 | +$10.7M | 20.9% |
| A Allovir Inc | Exited | −16,635,286 | −$6.99M | — |
| Kalaris Therapeutics Inc | New | +723,273 | +$5.81M | 0.5% |
| IO Ikena Oncology Inc | Trimmed | −849,193 | −$1.09M | 0.1% |
| Agenus Inc | Exited | −231,663 | −$635K | — |
| BB Barinthus Biotherapeutics Pl | Trimmed | −250,496 | −$244K | — |
| Kronos Bio Inc | Exited | −188,567 | −$179K | — |
Loading...
